How many insider trades does FilingIQ track for KRYS?

FilingIQ tracks 659 Form 4 insider transactions for KRYS (Krystal Biotech, Inc.), covering filings from Sep 22, 2017 onwards. 87 of those were filed in the last 90 days.

Are KRYS insiders net buyers or net sellers?

Across the full Form 4 history for KRYS, 11 transactions (2%) were open-market purchases and 501 (76%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KRYS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KRYS in?

Krystal Biotech, Inc. (KRYS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.69B.

KRYS insider trading

NasdaqGS Healthcare

Krystal Biotech, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

659

Last 90 days

Buys / sells

2% / 76%

Market cap

$7.69B

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Company website: www.krystalbio.com

KRYS insider activity at a glance

FilingIQ has scored 659 insider transactions for KRYS since Sep 22, 2017. The most recent filing in our index is dated Mar 4, 2026.

Across the full history, 11 open-market purchases and 501 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KRYS insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KRYS trades on FilingIQ Raw filings on SEC EDGAR

Latest KRYS Form 4 filings

Krishnan Krish S President and CEO

S May 31, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding KRYS

Avoro Capital Advisors LLC

$712.23M · 7.0% of AUM

Frazier Life Sciences Management, L.P.

$79.20M · 4.9% of AUM

Ikarian Capital, LLC

$66.72M · 7.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for KRYS?: FilingIQ tracks 659 Form 4 insider transactions for KRYS (Krystal Biotech, Inc.), covering filings from Sep 22, 2017 onwards. 87 of those were filed in the last 90 days.
Are KRYS insiders net buyers or net sellers?: Across the full Form 4 history for KRYS, 11 transactions (2%) were open-market purchases and 501 (76%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KRYS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KRYS in?: Krystal Biotech, Inc. (KRYS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.69B.

Methodology & sources

Every KRYS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.